Programmed Cell Death 1 Receptor
"Programmed Cell Death 1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE.
| Descriptor ID |
D061026
|
| MeSH Number(s) |
D12.776.543.750.705.222.875 D23.050.301.264.894.790 D23.101.100.894.790
|
| Concept/Terms |
Programmed Cell Death 1 Receptor- Programmed Cell Death 1 Receptor
- PD-1 Receptor
- PD 1 Receptor
- Receptor, PD-1
- CD279 Antigen
- Antigen, CD279
- PD1 Receptor
- Receptor, PD1
- Programmed Cell Death 1 Protein
- Antigens, CD279
- CD279 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Programmed Cell Death 1 Receptor".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- Programmed Cell Death 1 Receptor [D12.776.543.750.705.222.875]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- Programmed Cell Death 1 Receptor [D23.050.301.264.894.790]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- Programmed Cell Death 1 Receptor [D23.101.100.894.790]
Below are MeSH descriptors whose meaning is more specific than "Programmed Cell Death 1 Receptor".
This graph shows the total number of publications written about "Programmed Cell Death 1 Receptor" by people in this website by year, and whether "Programmed Cell Death 1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 2 | 2 | 4 |
| 2015 | 3 | 3 | 6 |
| 2016 | 2 | 5 | 7 |
| 2017 | 4 | 5 | 9 |
| 2018 | 7 | 5 | 12 |
| 2019 | 5 | 17 | 22 |
| 2020 | 10 | 5 | 15 |
| 2021 | 3 | 7 | 10 |
| 2022 | 1 | 10 | 11 |
| 2023 | 3 | 3 | 6 |
| 2024 | 6 | 6 | 12 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Programmed Cell Death 1 Receptor" by people in Profiles.
-
Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high grade serous carcinoma is dependent on chemotherapy response score. Hum Pathol. 2025 May; 159:105800.
-
Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers. Neoplasia. 2025 May; 63:101157.
-
NK cells restrain cytotoxic CD8+ T cells in the submandibular gland via PD-1-PD-L1. Sci Immunol. 2024 12 20; 9(102):eadl2967.
-
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer. Clin Cancer Res. 2024 Dec 16; 30(24):5593-5600.
-
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan; 637(8048):1218-1227.
-
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell Rep Med. 2024 Nov 19; 5(11):101799.
-
Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study. J Immunother Cancer. 2024 Nov 03; 12(11).
-
Venetoclax Induces BCL-2-Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti-PD-1 Checkpoint Blockade. Cancer Immunol Res. 2024 Aug 01; 12(8):1074-1089.
-
Mitochondria-Targeted Multifunctional Nanoparticles Combine Cuproptosis and Programmed Cell Death-1 Downregulation for Cancer Immunotherapy. Adv Sci (Weinh). 2024 Sep; 11(35):e2403520.
-
Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature. 2024 Jun; 630(8018):968-975.